{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:35:10Z","timestamp":1788593710327,"version":"build-2803163510"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"\n Background and Aims:<\/jats:title>\n The NAFLD activity score was developed to measure histologic changes in NAFLD during therapeutic trials. Hepatocyte ballooning (HB) is the most specific feature in steatohepatitis diagnosis, yet the impact of variations in HB has not been incorporated.<\/jats:p>\n <\/jats:sec>\n \n Approach and Results:<\/jats:title>\n Liver biopsies from patients enrolled in the NASH Clinical Research Network with an initial diagnosis of NASH or NAFL (n=1688) were evaluated to distinguish classic hepatocyte ballooning (cHB) from smaller, nonclassic hepatocyte ballooning (nHB), and also to designate severe ballooning and assign an extended hepatocyte ballooning (eB) score [0 points, no ballooning (NB); 1 point, few or many nHB; 2 points, few cHB; 3 points, many cHB; 4 points, severe cHB] to the biopsy assessment. The eB score was reproducible among NASH CRN liver pathologists (weighted kappa 0.76) and was significantly associated with older age (mean 52.1\u00a0y, cHB; 48.5\u00a0y, nHB, p<\/jats:italic><0.001), gender (72.3% female, cHB; 54.5% female, nHB, p<\/jats:italic><0.001), diabetes (49.8% diabetes, cHB; 28.2% diabetes, nHB, p<\/jats:italic><0.001), metabolic syndrome (68.5% metabolic syndrome, nHB; 50.2% metabolic syndrome, NB, p<\/jats:italic><0.001), and body mass index [33.2, 34.2, 35 mean body mass index (kg\/m2<\/jats:sup>); NB, nHB, and cHB, respectively, p<\/jats:italic><0.05]. Finally, fibrosis stage, as a marker of disease severity, was significantly correlated with the eB score (p<\/jats:italic><0.001).<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n The eB score allows for a reproducible and more precise delineation of the range of ballooned hepatocyte morphology and corresponds with both clinical features of NASH and fibrosis stage.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/hc9.0000000000000033","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T21:36:10Z","timestamp":1675287370000},"page":"e0033-e0033","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance"],"prefix":"10.1097","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6229-7928","authenticated-orcid":false,"given":"Ryan M.","family":"Gill","sequence":"first","affiliation":[{"name":"Department of Pathology, University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9868-8269","authenticated-orcid":false,"given":"Daniela","family":"Allende","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia H.","family":"Belt","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7016-2636","authenticated-orcid":false,"given":"Cynthia A.","family":"Behling","sequence":"additional","affiliation":[{"name":"Sharp Memorial Hospital, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4639-1660","authenticated-orcid":false,"given":"Oscar W.","family":"Cummings","sequence":"additional","affiliation":[{"name":"Department of Pathology, Indiana University, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4959-751X","authenticated-orcid":false,"given":"Cynthia D.","family":"Guy","sequence":"additional","affiliation":[{"name":"Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saint Louis University, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-7398","authenticated-orcid":false,"given":"Brent A.","family":"Neuschwander-Tetri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-5748","authenticated-orcid":false,"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-8751","authenticated-orcid":false,"given":"James","family":"Tonascia","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3219-9451","authenticated-orcid":false,"given":"Mark L.","family":"Van Natta","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-4504","authenticated-orcid":false,"given":"Laura A.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1691-5155","authenticated-orcid":false,"given":"Goro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3004-8799","authenticated-orcid":false,"given":"Matthew","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-4453","authenticated-orcid":false,"given":"David E.","family":"Kleiner","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2]]},"reference":[{"key":"R1-20240826","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"R2-20240826","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"R3-20240826","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R4-20240826","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"R5-20240826","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2001-12925","article-title":"Nonalcoholic steatohepatitis: definition and pathology","volume":"21","author":"Brunt","year":"2001","journal-title":"Semin Liver Dis"},{"key":"R6-20240826","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0032-1306421","article-title":"Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research","volume":"32","author":"Kleiner","year":"2012","journal-title":"Semin Liver Dis"},{"key":"R7-20240826","first-page":"434","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"R8-20240826","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology"},{"key":"R9-20240826","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.path.2013.03.002","article-title":"Nonalcoholic steatohepatitis: diagnostic challenges","volume":"6","author":"Gill","year":"2013","journal-title":"Surg Pathol Clin"},{"key":"R10-20240826","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2010.04.031","article-title":"Hepatocellular ballooning in NASH","volume":"53","author":"Caldwell","year":"2010","journal-title":"J Hepatol"},{"key":"R11-20240826","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"R12-20240826","first-page":"288A","article-title":"Extending the ballooning score beyond 2: a proposal for a new balloon score","volume":"62","author":"Kleiner","year":"2015","journal-title":"Hepatology"},{"key":"R13-20240826","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.32475","article-title":"Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score","volume":"76","author":"Pai","year":"2022","journal-title":"Hepatology"},{"key":"R14-20240826","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"R15-20240826","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"R16-20240826","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"R17-20240826","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/hep.22724","article-title":"Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD\u2014clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network","volume":"49","author":"Brunt","year":"2009","journal-title":"Hepatology"},{"key":"R18-20240826","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2008.01.026","article-title":"Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis","volume":"48","author":"Lackner","year":"2008","journal-title":"J Hepatol"},{"key":"R19-20240826","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/egh.11.8","article-title":"Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist\u2019s perspective","volume":"5","author":"Lackner","year":"2011","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R20-20240826","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2022.01.011","article-title":"Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD","volume":"76","author":"Brunt","year":"2022","journal-title":"J Hepatol"},{"key":"R21-20240826","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.30418","article-title":"Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: Results from the Nonalcoholic Steatohepatitis Clinical Research Network treatment trials","volume":"70","author":"Brunt","year":"2019","journal-title":"Hepatology"},{"key":"R22-20240826","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"suppl 2","key":"R23-20240826","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12072-013-9446-z","article-title":"Current histological classification of NAFLD: strength and limitations","volume":"7","author":"Bedossa","year":"2013","journal-title":"Hepatol Int"},{"key":"R24-20240826","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"R25-20240826","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J Hepatol"},{"key":"R26-20240826","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41575-020-00363-8","article-title":"Determining the reliability of liver biopsies in NASH clinical studies","volume":"17","author":"Longerich","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T15:06:24Z","timestamp":1724684784000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hc9.0000000000000033","relation":{},"ISSN":["2471-254X"],"issn-type":[{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"2022-07-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}